The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme: Laboratory investigation

Journal of Neurosurgery

Volumn 109, Issue 5, 2008, Pages 842-848

  Khatri, Rina G ^a   Navaratne, Kapila ^a   Weil, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Mutation; Oncogene; Radiation therapy; Surgery; Survival; TP53 gene; Tumor suppressor gene

Indexed keywords

DNA; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ISOLATION; GENETIC ASSOCIATION; GENOTYPE; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MUTANT; MUTATION; NEOPLASM; OVERALL SURVIVAL; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REACTION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; WILD TYPE; ADULT; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; NUCLEOTIDE SEQUENCE; ONSET AGE; PHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DNA, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 58149168580     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/JNS/2008/109/11/0842     Document Type: Article

References (39)

1. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, et al: A chromatin-associated and transcriptionally inactive p53-mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280:26776-26787, 2005
2. Atwal GS, Bond GL, Metsuyanim S, Papa M, Friedman E, Distelman-Menachem T, et al: Haplotype structure and selection of the MDM 2 oncogene in humans. Proc Natl Acad Sci U S A 104:4524-4529, 2007 (Pubitemid 47186258)
3. Bhargava V, Thor A, Deng G, Ljung BM, Moore DH 2nd, Waldman F: The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 7:361-368, 1994
4. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ: A functional polymorphism in the EGF gene is found with increased frequen- cy in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 64:1220-1223, 2004 (Pubitemid 38235584)
5. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56:180-185, 1997 (Pubitemid 27461181)
6. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602, 2004 (Pubitemid 39535748)
7. Bond GL, Hu W, Levine A: A single nucleotide polymorphism in the MDM2 gene: from molecular and cellular explanation to clinical effect. Cancer Res 65:5481-5484, 2005 (Pubitemid 40911143)
8. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al: Aberrant p53, mdm2 and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8:180-187, 2002 (Pubitemid 34101475)
9. Cobbs CS, Whisenhunt TR, Wesemann DR, Harkins LE, Van Meir EG, Samanta M: Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 63:8670-8673, 2003
10. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al: MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12:4867-4871, 2006 (Pubitemid 44338572)
11. Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55:96-107, 1999 (Pubitemid 29077858)
12. He J, Reifenberger G, Liu L, Collins VP, James CD: Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 11:91-96, 1994 (Pubitemid 24300183)
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991 (Pubitemid 21917115)
14. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al: The role of p53 and mdm2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582-9587, 2005 (Pubitemid 41508029)
15. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, et al: Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218-2223, 2006 (Pubitemid 43673244)
16. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H: MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16:2717-2723, 2007
17. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60:417-424, 2000 (Pubitemid 30070771)
18. Kelley TW, Tubbs RR, Prayson RA: Molecular diagnostic techniques for the clinical evaluation of gliomas. Diagn Mol Pathol 14:1-8, 2005
19. Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Central Nervous System. World Health Organization Classification of Tumours, ed 2. Lyon: IARC, 2000
20. Kleihues P, Ohgaki H: Primary and secondary glioblasto mas: from concept to clinical diagnosis. Neuro Oncol 1:44-51, 1999
21. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 15:1-4, 1996 (Pubitemid 26072881)
22. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001 (Pubitemid 32799739)
23. Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268, 1994 (Pubitemid 24228676)
24. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al: Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285-288, 2006 (Pubitemid 43264712)
25. Moll UM, Petrenko O: The MDM2-p53 interaction. Mol Cancer Res 1:1001-1008, 2003
26. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al: Genetic pathways to glioblastoma: a population- based study. Cancer Res 64:6892-6899, 2004 (Pubitemid 39330996)
27. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24:4434-4440, 2006 (Pubitemid 46630981)
28. Onel K, Cordon-Cardo C: MDM2 and prognosis. Mol Cancer Res 2:1-8, 2004 (Pubitemid 38167102)
29. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051-4058, 2005 (Pubitemid 40775641)
30. Ryan KM, Phillips AC, Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13:332-337, 2001
31. Schiebe M, Ohneseit P, Hoffmann W, Schiebe M, Ohneseit P, Hoffmann W, et al: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 49:197-203, 2000 (Pubitemid 32106781)
32. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, et al: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122-1128, 2001 (Pubitemid 32174434)
33. Walsh CS, Miller CW, Karlan BY, Koeffler HP: Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104:660-664, 2007
34. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223, 1996 (Pubitemid 26246377)
35. Weisz L, Oren M, Rotter V: Transcription regulation by mutant p53. Oncogene 26:2202-2211, 2007 (Pubitemid 46536644)
36. Wrensch M, McMillan A, Wiencke J, Wiemels J, Kelsey K, Patoka J, et al: Nonsynonymous coding single-nucleotide poly morphisms spanning the genome in relation to glioblastoma survival and age at diagnosis. Clin Cancer Res 13:197-205, 2007 (Pubitemid 46121869)
37. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993 (Pubitemid 24036020)
38. Xu Y: Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene 27:3501-3507, 2008
39. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R: MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 279:16000-16006, 2004 (Pubitemid 38509289)